



Journal of the British Thoracic Society

Impact Factor: 9.655

**Editors-in-Chief**

N Hart (UK)  
G Jenkins (UK)  
AR Smyth (UK)

**Deputy Editors**

N Kaminski (USA)  
M Rosenfeld (USA)

**Associate Editors**

D Baldwin (UK)	J-L Pepin (France)
R Chambers (UK)	M Polkey (UK)
T Coleman (UK)	J Quint (UK)
GJ Criner (USA)	N Rahman (UK)
J Davies (UK)	K Robinson (USA)
A Floto (UK)	S Shaheen (UK)
M Griffiths (UK)	R Stevens (USA)
L Heaney (UK)	A Vonk Noordegraaf (The Netherlands)
N Hopkinson (UK)	C Wainwright (Australia)
S Janes (UK)	T Wilkinson (UK)
B Kampman (UK)	P Wolters (USA)
B Mohkelesi (USA)	

**Statistical Editors**

A Douiri (UK)  
C Flach (UK)  
C Jackson (UK)  
S Stanojevic (USA)  
R Szczesniak (USA)  
B Wagner (USA)  
Y Wang (UK)

**Journal Club Editor**

P Murphy (UK)

**President, British Thoracic Society**

Dr M Elliott

**Editorial Office**

Thorax, BMA House, Tavistock Square,  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6373  
E: [thorax@bmj.com](mailto:thorax@bmj.com)

Twitter: @ThoraxBMJ

ISSN: 0040-6376 (print)  
ISSN: 1468-3296 (online)

**Disclaimer:** Thorax is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of Thorax.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of Thorax or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2019 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of Thorax.

Thorax is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Thorax (ISSN No: 0040-6376) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Thorax, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**1 Summary of recommendations and good practice points**

**Section 1**

- 10 Introduction
- 10 Target audience for the guideline
- 10 Scope of the guideline
- 10 Areas not covered by the guideline
- 10 Definition

**Section 2**

- 10 Methodology
- 10 Clinical Questions and Literature Search
- 10 Appraisal of Literature
- 11 Considered Judgement and Grading of Evidence
- 11 Drafting the Guideline
- 11 Guideline Group Members and Declarations of Interest
- 11 Stakeholders

**Section 3**

- 11 How common is bronchiectasis?

**Section 4**

- 12 How should the diagnosis of bronchiectasis be determined?
- 12 Imaging

**Section 5**

- 12 In whom should the diagnosis of bronchiectasis be suspected?
- 13 COPD
- 13 Alpha-1 antitrypsin deficiency (A1AT)
- 13 Asthma
- 13 Rhinosinusitis
- 13 Chronic systemic infection
- 13 Rheumatoid arthritis
- 13 Other connective tissue diseases
- 13 Inflammatory bowel disease

**Section 6**

- 14 Investigations for causes of bronchiectasis
- 14 Standard laboratory tests

- 15 Tests for specific disease groups with associated bronchiectasis
- 15 Allergic bronchopulmonary aspergillosis
- 16 Immune dysfunction
- 16 Serum immunoglobulins (IgG, IgA, & IgM) and electrophoresis
- 16 Full blood count (FBC)
- 16 Measurement of baseline specific antibody levels against capsular polysaccharides of *Streptococcus pneumoniae*
- 17 Rheumatoid Arthritis
- 17 Recurrent aspiration
- 17 Cystic fibrosis
- 17 Ciliary dysfunction
- 18 Young's syndrome
- 18 Alpha-1 antitrypsin deficiency
- 18 Congenital Causes
- 18 Investigations of lung microbiology

**Section 7**

- 19 Prognosis: What is the outlook for these patients?

**Section 8**

- 19 Severity scoring

**Section 9**

- 20 Stable state treatment
- 20 Airway clearance techniques
- 20 Which patients should be taught airway clearance techniques?
- 21 Adherence
- 21 Which airway clearance techniques should be taught?
- 24 How often should patients carry out airway clearance techniques? How long should an airway clearance session last?
- 24 How soon should the patient be reviewed after the initial assessment?
- 24 Mucoactives in bronchiectasis
- 25 What is the evidence for long term anti-inflammatory therapies in bronchiectasis?

**MORE CONTENTS ►**

This article has been chosen by the Editors to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.  
See <http://authors.bmj.com/open-access/>

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics  
<http://publicationethics.org/>

Member since 2009  
JMO3979



- 27 What treatments improve outcomes for patients with stable bronchiectasis?
- 30 Does long term bronchodilator treatment improve outcomes for patients with bronchiectasis?
- 31 Pulmonary Rehabilitation
- 32 Inspiratory Muscle Training
- 32 Field Walking Tests
- 33 What is the role of surgery in managing bronchiectasis?
- 33 Lung transplantation for bronchiectasis
- 34 What is the role of influenza and pneumococcal vaccination in management of bronchiectasis?
- 35 Treatment of respiratory failure
- 36 Bronchiectasis and other treatments

### Section 10

- 36 Do pathogens have an impact on prognosis in bronchiectasis?

### Section 11

- 37 What is the evidence for the role of viruses/fungal disease in patients with bronchiectasis?

### Section 12

- 37 Does eradication of potentially pathogenic microorganisms improve outcomes in patients with stable bronchiectasis?

### Section 13

- 38 Exacerbations
- 38 Does antibiotic therapy improve outcomes in patients with an exacerbation of bronchiectasis?

### Section 14

- 40 Specific treatments
- 40 What treatments improve outcomes in patients with bronchiectasis and ABPA?
- 41 Does immunoglobulin replacement treatment improve outcomes in patients with bronchiectasis due to antibody deficiency?
- 41 Gastro-oesophageal reflux disease (GORD) and bronchiectasis
- 42 What is the prevalence of rhinosinusitis in patients with stable bronchiectasis and what are the outcomes of treatment?
- 42 Should treatment of bronchiectasis be altered in the presence of co-morbidities?

### Section 15

- 44 How should we monitor bronchiectasis?

### Section 16

- 45 Is there a role for microbiological sensitivity testing?

### Section 17

- 45 Is there any evidence of cross-infection with pathogenic organisations?

### Section 18

- 46 Specialist vs non-specialist setting

### Section 19

- 46 What are the complications of bronchiectasis?

### Section 20

- 47 Summary of research recommendations

### Tables

- Table 1** Quick Summary Guide
- Table 2** Levels of evidence
- Table 3** Grades of recommendation
- Table 4** Variables involved in calculating the severity score in the Bronchiectasis Severity Index
- Table 5** Variables involved in calculating severity in the FACED score
- Table 6** Common organisms associated with acute exacerbation of bronchiectasis and suggested antimicrobial agents- adults
- Table 7** Routine monitoring tests

### Figures

- 4 Figure 1 Management of the deteriorating patient
- 5 Figure 2 Stepwise management
- 26 Figure 3 Physiotherapy management-stepwise airway clearance
- 26 Figure 4 Airway clearance – exacerbation
- 43 Figure 5 Algorithm for initial assessment and treatment – rhinosinusitis

### Appendices

- 55 Appendix 1: Guideline group members
- 55 Appendix 2: Protocol for test dose of a nebulised antibiotic
- 55 Appendix 3: Long term antibiotic regimes
- 56 Appendix 4: Specialist immunology investigations
- 59 Appendix 5: Summary table of papers for investigations/causes
- 62 Appendix 6: Causes of bronchiectasis
- 65 Appendix 7: Studies of lower respiratory tract microbiology in bronchiectasis patients
- 67 Appendix 8: Summary of research recommendations in PICO format

### Online appendices

- Online appendix 1: Clinical questions
- Online appendix 2: Literature search details
- Online appendix 3: Evidence tables
- Online appendices are available at [www.brit-thoracic.org.uk](http://www.brit-thoracic.org.uk)